The Pharmacology and Therapeutic Potential of Plant Cannabinoids

  • Maria Grazia CascioEmail author
  • Roger G. Pertwee
  • Pietro Marini


The plant Cannabis sativa has been widely used by humans over many centuries as a source of fibre, for medicinal purposes, for religious ceremonies and as a recreational drug. Since the discovery of its main psychoactive ingredient, Δ9-tetrahydrocannabinol (THC), significant progress has been made towards the understanding (1) of the in vitro and in vivo pharmacology both of THC and of certain other cannabis-derived compounds, and (2) of the potential and actual uses of these “phytocannabinoids” as medicines. There is now extensive evidence that the pharmacological effects of some widely-studied phytocannabinoids, are due to their ability to interact with cannabinoid receptors and/or with other kinds of pharmacological targets, including non-cannabinoid receptors, and this makes the pharmacology of the phytocannabinoids rather complex and interesting. In this chapter, we provide an overview of the in vitro pharmacology of five selected phytocannabinoids and report findings that have identified potential new therapeutic uses for these compounds.


Mouse Brain Membrane House Musk Shrew TRPM8 Cation Channel Cannabidiolic Acid TRPV3 Cation Channel 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.















Cannabidiolic acid




Cannabigerolic acid


Tetrahydrocannabinolic acid


Tetrahydrocannabivarinic acid


Transient receptor potential


Peroxisome-proliferator activated receptor


G-protein coupled receptor








6aR,10aR)- 9-(Hydroxymethyl)- 6,6-dimethyl- 3-(2-methyloctan-2-yl)- 6a,7,10,10a-tetrahydrobenzo [c]chromen- 1-ol


[2,3-Dihydro-5-methyl-3-(4-morpholinylmethyl)pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl]-1-naphthalenylmethanone mesylate




Guanosine 5′-O-[gamma-thio]triphosphate)


Adenosine monophosphate


Extracellular signal-regulated kinases


Chinese hamster ovary


Negative allosteric modulator


N-(Piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide hydrochloride


(S)-N-tert-Butyl-3-(4-(2-methoxyphenyl)-piperazin-1-yl)-2-phenylpropanamide dihydrochloride


N-[2-[4-(2-Methoxyphenyl)-1-piperazinyl]ethyl]-N-2-pyridinylcyclohexanecarboxamide maleate




  1. Alexander SP (2016) Therapeutic potential of cannabis-related drugs. Prog Neuropsychopharmacol Biol Psychiatry 64:157–166. ReviewGoogle Scholar
  2. Anavi-Goffer S, Baillie G, Irving AJ, Gertsch J, Greig IR, Pertwee RG, Ross RA (2012) Modulation of L-α-lysophosphatidylinositol/GPR55 mitogen-activated protein kinase (MAPK) signaling by cannabinoids. J Biol Chem 287:91–104CrossRefPubMedGoogle Scholar
  3. Baek SH, Kim YO, Kwag JS, Choi KE, Jung WY, Han DS (1998) Boron trifluoride etherate on silica-A modified Lewis acid reagent (VII). Antitumor activity of Cannabigerol against human oral epitheloid carcinoma cells. Arch Pharm Res 21:353–356CrossRefPubMedGoogle Scholar
  4. Bayewitch M, Rhee M-H, Avidor-Reiss T, Breuer A, Mechoulam R, Vogel Z (1996) (-)-Δ9-tetrahydrocannabinol antagonizes the peripheral cannabinoid receptor-mediated inhibition of adenylyl cyclase. J Biol Chem 271:9902–9905CrossRefPubMedGoogle Scholar
  5. Bolognini D, Costa B, Maione S, Comelli F, Marini P, Di Marzo V, Parolaro D, Ross RA, Gauson LA, Cascio MG, Pertwee RG (2010) The plant cannabinoid Δ9-tetrahydrocannabivarin can decrease signs of inflammation and inflammatory pain in mice. Br J Pharmacol 160:677–687CrossRefPubMedPubMedCentralGoogle Scholar
  6. Bolognini D, Cascio MG, Parolaro D, Pertwee RG (2012) AM630 behaves as a protean ligand at the human cannabinoid CB2 receptor. Br J Pharmacol 165:2561–2574CrossRefPubMedPubMedCentralGoogle Scholar
  7. Bolognini D, Rock EM, Cluny NL, Cascio MG, Limebeer CL, Duncan M, Stott CG, Javid FA, Parker LA, Pertwee RG (2013) Cannabidiolic acid prevents vomiting in Suncus murinus and nausea-induced behaviour in rats by enhancing 5-HT1A receptor activation. Br J Pharmacol 168:1456–1470CrossRefPubMedPubMedCentralGoogle Scholar
  8. Brown NK, Harvey DJ (1990) In vitro metabolism of cannabichromene in 7 common laboratory animals. Drug Metab Dispos 18:1065–1070PubMedGoogle Scholar
  9. Carrier EJ, Auchampach JA, Hillard CJ (2006) Inhibition of an equilibrative nucleoside transporter by cannabidiol: a mechanism of cannabinoid immunosuppression. Proc Natl Acad Sci U S A 103:7895–7900CrossRefPubMedPubMedCentralGoogle Scholar
  10. Cascio MG, Marini P (2015) Biosynthesis and fate of endocannabinoids. In: Pertwee RG (ed) Endocannabinoids. Springer, Heidelberg, pp 39–58CrossRefGoogle Scholar
  11. Cascio MG, Pertwee RG (2014) Known pharmacological actions of nine non-psychotropic phytocannabinoids. In: Pertwee RG (ed) Handbook of Cannabis. Oxford University Press, Oxford, pp 137–156CrossRefGoogle Scholar
  12. Cascio MG, Gauson LA, Stevenson LA, Ross RA, Pertwee RG (2010) Evidence that the plant cannabinoid cannabigerol is a highly potent alpha2-adrenoceptor agonist and moderately potent 5HT1A receptor antagonist. Br J Pharmacol 159:129–141Google Scholar
  13. Cascio MG, Zamberletti E, Marini P, Parolaro D, Pertwee RG (2015) The phytocannabinoid, Δ9-tetrahydrocannabivarin, can act through 5-HT1A receptors to produce antipsychotic effects. Br J Pharmacol 172:1305–1318CrossRefPubMedPubMedCentralGoogle Scholar
  14. Cluny NL, Naylor RJ, Whittle BA, Javid FA (2008) The effects of cannabidiol and tetrahydrocannabinol on motion-induced emesis in Suncus murinus. Basic Clin Pharmacol Toxicol 103:150–156CrossRefPubMedGoogle Scholar
  15. Costa B, Trovato AE, Comelli F, Giagnoni G, Colleoni M (2007) The non-psychoactive cannabis constituent cannabidiol is an orally effective therapeutic agent in rat chronic inflammatory and neuropathic pain. Eur J Pharmacol 556:75–83CrossRefPubMedGoogle Scholar
  16. De Petrocellis L, Ligresti A, Moriello AS, Allarà M, Bisogno T, Petrosino S, Stott CG, Di Marzo V (2011) Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes. Br J Pharmacol 163:1479–1494CrossRefPubMedPubMedCentralGoogle Scholar
  17. De Petrocellis L, Orlando P, Moriello AS, Aviello G, Stott C, Izzo AA, Di Marzo V (2012) Cannabinoid actions at TRPV channels: effects on TRPV3 and TRPV4 and their potential relevance to gastrointestinal inflammation. Acta Physiol 204:255–266CrossRefGoogle Scholar
  18. De Petrocellis L, Vellani V, Schiano-Moriello A, Marini P, Magherini PC, Orlando P, Di Marzo V (2008) Plant-derived cannabinoids modulate the activity of transient receptor potential channels of ankyrin type-1 and melastatin type-8. J Pharmacol Exp Ther 325:1007–1015CrossRefPubMedGoogle Scholar
  19. Devane WA, Dysarz FA, Johnson MR, Melvin LS, Howlett AC (1988) Determination and characterization of a cannabinoid receptor in rat brain. Mol Pharmacol 34:605–613PubMedGoogle Scholar
  20. Duran M, Pérez E, Abanades S, Vidal X, Saura C, Majem M, Arriola E, Rabanal M, Pastor A, Farre M, Rams N, Laporte JR, Capella D (2010) Preliminary efficacy and safety of an oromucosal standardized cannabis extract in chemotherapy-induced nausea and vomiting. Br J Clin Pharmacol 70:656–663CrossRefPubMedPubMedCentralGoogle Scholar
  21. Gallily R, Even-Chen T, Katzavian G, Lehmann D, Dagan A, Mechoulam R (2003) γ-Irradiation enhances apoptosis induced by cannabidiol, a non-psychotropic cannabinoid, in cultured HL-60 myeloblastic leukemia cells. Leuk Lymphoma 44:1767–1773CrossRefPubMedGoogle Scholar
  22. Galve-Roperh I, Sánchez C, Cortés ML, Gómez del Pulgar T, Izquierdo M, Guzmán M (2000) Anti-tumoral action of cannabinoids: involvement of sustained ceramide accumulation and extracellular signal-regulated kinase activation. Nat Med 6:313–319CrossRefPubMedGoogle Scholar
  23. Gill EW, Paton WDM, Pertwee RG (1970) Preliminary experiments on the chemistry and pharmacology of cannabis. Nature 228:134–136CrossRefPubMedGoogle Scholar
  24. Govaerts SJ, Hermans E, Lambert DM (2004) Comparison of cannabinoid ligands affinities and efficacies in murine tissues and in transfected cells expressing human recombinant cannabinoid receptors. Eur J Pharm Sci 23:233–243CrossRefPubMedGoogle Scholar
  25. Guindon J, Hohmann AG (2008) Cannabinoid CB2 receptors: a therapeutic target for the treatment of inflammatory and neuropathic pain. Br J Pharmacol 153:319–334CrossRefPubMedGoogle Scholar
  26. Guzmán M, Duarte MJ, Blázquez C, Ravina J, Rosa MC, Galve-Roperh I, Sánchez C, Velasco G, González-Feria L (2006) A pilot clinical study of Delta9-tetrahydrocannabinol in patients with recurrent glioblastoma multiforme. Br J Cancer 95:197–203Google Scholar
  27. Hart S, Fischer OM, Ullrich A (2004) Cannabinoids induce cancer cell proliferation via tumor necrosis factor alpha-converting enzyme (TACE/ADAM17)-mediated transactivation of the epidermal growth factor receptor. Cancer Res 64:1943–1950CrossRefPubMedGoogle Scholar
  28. Howlett AC (2002) The cannabinoid receptors. Prostaglandins Other Lipid Mediat 68–9:619–631CrossRefGoogle Scholar
  29. Howlett AC (2005) Cannabinoid receptor signaling. In: Pertwee RG (ed) Cannabinoids. Springer, Heidelberg, pp 53–79CrossRefGoogle Scholar
  30. Howlett AC, Barth F, Bonner TI, Cabral G, Casellas P, Devane WA, Felder CC, Herkenham M, Mackie K, Martin BR, Mechoulam R, Pertwee RG (2002) International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev 54:161–202. ReviewGoogle Scholar
  31. Izzo AA, Borrelli F, Capasso R, Di Marzo V, Mechoulam R (2009) Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb. Trends Pharmacol Sci 30:515–527, 609Google Scholar
  32. Kelley BG, Thayer SA (2004) Δ9-Tetrahydrocannabinol antagonizes endocannabinoid modulation of synaptic transmission between hippocampal neurons in culture. Neuropharmacology 46:709–715CrossRefPubMedGoogle Scholar
  33. Kimura M, Okamoto K (1970) Distribution of tetrahydrocannabinolic acid in fresh wild cannabis. Experientia 26:819–820CrossRefPubMedGoogle Scholar
  34. Kramer JL (2015) Medical marijuana for cancer. CA-Cancer J Clin 65:109–122CrossRefPubMedGoogle Scholar
  35. Kwiatkowska M, Parker LA, Burton P, Mechoulam R (2004) A comparative analysis of the potential of cannabinoids and ondansetron to suppress cisplatin-induced emesis in the Suncus murinus (house musk shrew). Psychopharmacology 174:254–259CrossRefPubMedGoogle Scholar
  36. Laprairie RB, Bagher AM, Kelly MEM, Denovan-Wright EM (2015) Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor. Br J Pharmacol 172:4790–4805CrossRefPubMedPubMedCentralGoogle Scholar
  37. Ligresti A, Schiano Moriello A, Starowicz K, Matias I, Pisanti S, De Petrocellis L, Laezza C, Portella G, Bifulco M, Di Marzo V (2006) Antitumor activity of plant cannabinoids with emphasis on the effect of cannabidiol on human breast carcinoma. J Pharmacol Exp Ther 318:1375–1387CrossRefPubMedGoogle Scholar
  38. Massi P, Valenti M, Vaccani A, Gasperi V, Perletti G, Marras E, Fezza F, Maccarrone M, Parolaro D (2008) 5-lipoxygenase and anandamide hydrolase (FAAH) mediate the antitumor activity of cannabidiol, a non-psychoactive cannabinoid. J Neurochem 104:1091–1100CrossRefPubMedGoogle Scholar
  39. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI (1990) Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346:561–564CrossRefPubMedGoogle Scholar
  40. McKallip RJ, Jia WT, Schlomer J, Warren JW, Nagarkatti PS, Nagarkatti M (2006) Cannabidiol-induced apoptosis in human leukemia cells: a novel role of cannabidiol in the regulation of p22(phox) and Nox4 expression. Mol Pharmacol 70:897–908CrossRefPubMedGoogle Scholar
  41. Mechoulam R, Lander N, Varkony TH, Kimmel I, Becker O, Ben Zvi, Edery H, Porath G (1980) Stereochemical requirements for cannabinoid activity. J Med Chem 23:1068–1072CrossRefPubMedGoogle Scholar
  42. Mechoulam R, Feigenbaum JJ, Lander N, Segal M, Järbe TUC, Hiltunen AJ, Consroe P (1988) Enantiomeric cannabinoids—stereospecificity of psychotropic activity. Experientia 44:762–764CrossRefPubMedGoogle Scholar
  43. Munro S, Thomas KL, Abu-Shaar M (1993) Molecular characterization of a peripheral receptor for cannabinoids. Nature 365:61–65CrossRefPubMedGoogle Scholar
  44. Munson AE, Harris LS, Friedman MA, Dewey WL, Carchman RA (1975) Anti-neoplastic activity of cannabinoids. J Nat Cancer Instit 55:587–602CrossRefGoogle Scholar
  45. Onaivi ES, Ishiguro H, Gong JP, Patel S, Perchuk A, Meozzi PA, Myers L, Mora Z, Tagliaferro P, Gardner E, Brusco A, Akinshola BE, Liu QR, Hope B, Iwasaki S, Arinami T, Teasenfitz L, Uhl GR (2006) Discovery of the presence and functional expression of cannabinoid CB2 receptors in brain. Ann N Y Acad Sci 1074:514–536CrossRefPubMedGoogle Scholar
  46. O’Sullivan SE (2007) Cannabinoids go nuclear: evidence for activation of peroxisome proliferator-activated receptors. Br J Pharmacol 152:576–582CrossRefPubMedPubMedCentralGoogle Scholar
  47. Oz M (2006) Receptor-independent effects of endocannabinoids on ion channels. Curr Pharm Design 12:227–239CrossRefGoogle Scholar
  48. Parker LA, Kwiatkowska M, Burton P, Mechoulam R (2004) Effect of cannabinoids on lithium-induced vomiting in the Suncus murinus (house musk shrew). Psychopharmacology 171:156–161CrossRefPubMedGoogle Scholar
  49. Parker LA, Rana SA, Limebeer CL (2008) Conditioned nausea in rats: assessment by conditioned disgust reactions, rather than conditioned taste avoidance. Can J Exp Psychol 62:198–209CrossRefPubMedGoogle Scholar
  50. Perez J, Ribera MV (2008) Managing neuropathic pain with Sativex®: a review of its pros and cons. Expert Opin Pharmacother 9:1189–1195CrossRefPubMedGoogle Scholar
  51. Pertwee RG (1988) The central neuropharmacology of psychotropic cannabinoids. Pharmacol Ther 36:189–261CrossRefPubMedGoogle Scholar
  52. Pertwee RG (1997) Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacol Ther 74:129–180PubMedGoogle Scholar
  53. Pertwee RG (2001) Cannabinoid receptors and pain. Prog Neurobiol 63:569–611CrossRefPubMedGoogle Scholar
  54. Pertwee RG (2004a) The pharmacology and therapeutic potential of cannabidiol. In: Di Marzo V (ed) Cannabinoids. Kluwer Academic/Plenum Publishers, New York, pp 32–83Google Scholar
  55. Pertwee RG (2004b) Pharmacological and therapeutic targets for Δ9-tetrahydrocannabinol and cannabidiol. Euphytica 140:73–82CrossRefGoogle Scholar
  56. Pertwee RG (2005) Pharmacological actions of cannabinoids. In: Pertwee RG (ed) cannabinoids. Springer-Verlag, Heidelberg, pp 1–51CrossRefGoogle Scholar
  57. Pertwee RG (2007) Cannabinoids and multiple sclerosis. Mol Neurobiol 36:45–59CrossRefPubMedGoogle Scholar
  58. Pertwee RG (2008) The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: Δ9-tetrahydrocannabinol, cannabidiol and Δ9-tetrahydrocannabivarin. Br J Pharmacol 153:199–215CrossRefPubMedGoogle Scholar
  59. Pertwee RG (2009) Emerging strategies for exploiting cannabinoid receptor agonists as medicines. Br J Pharmacol 156:397–411CrossRefPubMedPubMedCentralGoogle Scholar
  60. Pertwee RG (2010) Receptors and channels targeted by synthetic cannabinoid receptor agonists and antagonists. Curr Med Chem 17:1360–1381CrossRefPubMedPubMedCentralGoogle Scholar
  61. Pertwee RG (2015) Endocannabinoids and their pharmacological actions. In: Pertwee RG (ed) Endocannabinoids. Springer-Verlag, Heidelberg, pp 1–37CrossRefGoogle Scholar
  62. Pertwee RG, Ross RA (2002) Cannabinoid receptors and their ligands. Prostaglandins Leukot Essent Fatty Acids 66:101–121. ReviewGoogle Scholar
  63. Pertwee RG, Cascio MG (2014) Known pharmacological actions of delta-9-tetrahydrocannabinol and of four other chemical constituents of cannabis that activate cannabinoid receptors. In: Pertwee RG (ed) Handbook of Cannabis. Oxford University Press, Oxford, pp 115–136CrossRefGoogle Scholar
  64. Pertwee RG, Ross RA, Craib SJ, Thomas A (2002) (-)-Cannabidiol antagonizes cannabinoid receptor agonists and noradrenaline in the mouse vas deferens. Eur J Pharmacol 456:99–106CrossRefPubMedGoogle Scholar
  65. Pertwee RG, Howlett AC, Abood ME, Alexander SPH, Di Marzo V, Elphick MR, Greasley PJ, Hansen HS, Kunos G, Mackie K, Mechoulam R, Ross RA (2010) International union of basic and clinical pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB1 and CB2. Pharmacol Rev 62:588–631CrossRefPubMedPubMedCentralGoogle Scholar
  66. Pertwee RG, Thomas A, Stevenson LA, Ross RA, Varvel SA, Lichtman AH, Martin BR, Razdan RK (2007) The psychoactive plant cannabinoid, Δ9-tetrahydrocannabinol, is antagonized by Δ8- and Δ9-tetrahydrocannabivarin in mice in vivo. Br J Pharmacol 150:586–594CrossRefPubMedPubMedCentralGoogle Scholar
  67. Petitet F, Jeantaud B, Reibaud M, Imperato A, Dubroeucq M-C (1998) Complex pharmacology of natural cannabinoids: evidence for partial agonist activity of Δ9-tetrahydrocannabinol and antagonist activity of cannabidiol on rat brain cannabinoid receptors. Life Sci 63:PL1–6Google Scholar
  68. Pinsger M, Schimetta W, Volc D, Hiermann E, Riederer F, Pölz W (2006) Benefits of an add-on treatment with the synthetic cannabinomimetic nabilone on patients with chronic pain—a randomized controlled trial. Wien Klin Wochenschr 118:327–335Google Scholar
  69. Rahn EJ, Hohmann AG (2009) Cannabinoids as pharmacotherapies for neuropathic pain: from the bench to the bedside. Neurotherapeutics 6:713–737CrossRefPubMedPubMedCentralGoogle Scholar
  70. Ramer R, Hinz B (2008) Inhibition of cancer cell invasion by cannabinoids via increased expression of tissue inhibitor of matrix metalloproteinases-1. J Natl Cancer Inst 100:59–69CrossRefPubMedGoogle Scholar
  71. Rock EM, Bezaquen J, Limebeer CL, Parker LA (2008) Potential of the rat model of conditioned gaping to detect nausea produced by rolipram, a phosphodiesterase-4 (PDE4) inhibitor. Pharmacol Biochem Behav 91:537–541CrossRefPubMedGoogle Scholar
  72. Rock EM, Goodwin JM, Limebeer CL, Breuer A, Pertwee RG, Mechoulam R, Parker LA (2011) Interaction between non-psychotropic cannabinoids in marihuana: effect of cannabigerol (CBG) on the anti-nausea or anti-emetic effects of cannabidiol (CBD) in rats and shrews. Psychopharmacology 215:505–512CrossRefPubMedGoogle Scholar
  73. Rock EM, Bolognini D, Limebeer CL, Cascio MG, Anavi-Goffer S, Fletcher PJ, Mechoulam R, Pertwee RG, Parker LA (2012) Cannabidiol, a non-psychotropic component of cannabis, attenuates vomiting and nausea-like behaviour via indirect agonism of 5-HT1A somatodendritic autoreceptors in the dorsal raphe nucleus. Br J Pharmacol 165:2620–2634CrossRefPubMedPubMedCentralGoogle Scholar
  74. Ross RA (2009) The enigmatic pharmacology of GPR55. Trends Pharmacol Sci 30:156–163CrossRefPubMedGoogle Scholar
  75. Ruiz L, Miguel A, Diaz Laviada I (1999) Δ9-Tetrahydrocannabinol induces apoptosis in human prostate PC-3 cells via a receptor-independent mechanism. FEBS Lett 458:400–404CrossRefPubMedGoogle Scholar
  76. Russo EB, Burnett A, Hall B, Parker KK (2005) Agonistic properties of cannabidiol at 5-HT1A receptors. Neurochem Res 30:1037–1043CrossRefPubMedGoogle Scholar
  77. Ryberg E, Larsson N, Sjögren S, Hjorth S, Hermansson N-O, Leonova J, Elebring T, Nilsson K, Drmota T, Greasley PJ (2007) The orphan receptor GPR55 is a novel cannabinoid receptor. Br J Pharmacol 152:1092–1101CrossRefPubMedPubMedCentralGoogle Scholar
  78. Sacerdote P, Martucci C, Vaccani A, Bariselli F, Panerai AE, Colombo A, Parolaro D, Massi P (2005) The nonpsychoactive component of marijuana cannabidiol modulates chemotaxis and IL-10 and IL-12 production of murine macrophages both in vivo and in vitro. J Neuroimmunol 159:97–105CrossRefPubMedGoogle Scholar
  79. Sánchez C, Galve-Roperh I, Canova C, Brachet P, Guzmán M (1998) Delta9-tetrahydrocannabinol induces apoptosis in C6 glioma cells. FEBS Lett 436:6–10Google Scholar
  80. Shen M1, Thayer SA (1999) Delta9-tetrahydrocannabinol acts as a partial agonist to modulate glutamatergic synaptic transmission between rat hippocampal neurons in culture. Mol Pharmacol 55:8–13Google Scholar
  81. Showalter VM, Compton DR, Martin BR, Abood ME (1996) Evaluation of binding in a transfected cell line expressing a peripheral cannabinoid receptor (CB2): identification of cannabinoid receptor subtype selective ligands. J Pharmacol Exp Ther 278:989–999PubMedGoogle Scholar
  82. Sim LJ, Hampson RE, Deadwyler SA, Childers SR (1996) Effects of chronic treatment with delta9-tetrahydrocannabinol on cannabinoid-stimulated [35S]GTPgammaS autoradiography in rat brain. J Neurosci 16:8057–8066Google Scholar
  83. Skrabek RQ, Galimova L, Ethans K, Perry D (2008) Nabilone for the treatment of pain in fibromyalgia. J Pain 9:164–173Google Scholar
  84. Straiker A, Mackie K (2005) Depolarization-induced suppression of excitation in murine autaptic hippocampal neurones. J Physiol 569:501–517CrossRefPubMedPubMedCentralGoogle Scholar
  85. Thomas A, Ross RA, Saha B, Mahadevan A, Razdan RK, Pertwee RG (2004) 6″-Azidohex-2″-yne-cannabidiol: a potential neutral, competitive cannabinoid CB1 receptor antagonist. Eur J Pharmacol 487:213–221CrossRefPubMedGoogle Scholar
  86. Thomas A, Stevenson LA, Wease KN, Price MR, Baillie G, Ross RA, Pertwee RG (2005) Evidence that the plant cannabinoid Delta9-tetrahydrocannabivarin is a cannabinoid CB1 and CB2 receptor antagonist. Br J Pharmacol 146:917–926Google Scholar
  87. Thomas A, Baillie GL, Phillips AM, Razdan RK, Ross RA, Pertwee RG (2007) Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro. Br J Pharmacol 150:613–623CrossRefPubMedPubMedCentralGoogle Scholar
  88. Vaccani A, Massi P, Colombo A, Rubino T, Parolaro D (2005) Cannabidiol inhibits human glioma cell migration through a cannabinoid receptor-independent mechanism. Br J Pharmacol 144:1032–1036CrossRefPubMedPubMedCentralGoogle Scholar
  89. Van Sickle MD, Duncan M, Kingsley PJ, Mouihate A, Urbani P, Mackie K, Stella N, Makriyannis A, Piomelli D, Davison JS, Marnett LJ, Di Marzo V, Pittman QJ, Patel KD, Sharkey KA (2005) Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science 310:329–332CrossRefPubMedGoogle Scholar
  90. Walter L, Franklin A, Witting A, Wade C, Xie YH, Kunos G, Mackie K, Stella N (2003) Nonpsychotropic cannabinoid receptors regulate microglial cell migration. J Neurosci 23:1398–1405PubMedGoogle Scholar
  91. Yamaori S, Kushihara M, Yamamoto I, Watanabe K (2010) Characterization of major phytocannabinoids, cannabidiol and cannabinol, as isoform-selective and potent inhibitors of human CYP1 enzymes. Biochem Pharmacol 79:1691–1698CrossRefPubMedGoogle Scholar
  92. Yang KH, Galadari S, Isaev D, Petroianu G, Shippenberg TS, Oz M (2010) The nonpsychoactive cannabinoid cannabidiol inhibits 5-hydroxytryptamine3A receptor-mediated currents in Xenopus laevis oocytes. J Pharmacol Exp Ther 333:547–554CrossRefPubMedPubMedCentralGoogle Scholar
  93. Yin H, Chu A, Li W, Wang B, Shelton F, Otero F, Nguyen DG, Caldwell JS, Chen YA (2009) Lipid G protein-coupled receptor ligand identification using beta-arrestin PathHunter (TM) assay. J Biol Chem 284:12328–12338CrossRefPubMedPubMedCentralGoogle Scholar
  94. Zygmunt PM, Petersson J, Andersson DA, Chuang H, Sørgård M, Di Marzo V, Julius D, Högestätt ED (1999) Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. Nature 400:452–457CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG 2017

Authors and Affiliations

  • Maria Grazia Cascio
    • 1
    Email author
  • Roger G. Pertwee
    • 1
  • Pietro Marini
    • 1
  1. 1.School of Medicine, Medical Sciences and NutritionInstitute of Medical Sciences, University of AberdeenForesterhill, AberdeenUK

Personalised recommendations